Results 271 to 280 of about 955,174 (332)

Compounding and stability studies of liquid oral formulations of beta-blockers (bisoprolol, betaxolol, and nadolol) for paediatric patients. [PDF]

J Pharm Pharm Sci
Dubois L, Bouguergour C, Paoli-Lombardo R, Castera-Ducros C, Jean C, Fuchs M, Vanelle P, Rathelot P, Terme T, Curti C.   +9 more
europepmc   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Molten Pressure of Polyvinyl Chloride Under Processing Parameters in Counter-Rotating Twin-Screw Extrusion. [PDF]

Polymers (Basel)
Weng JS, Tsai HH, Liu JW.
europepmc   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Compounding and Use of Human Medicinal Products in Small Animal Practice: What Are the Perspectives of Veterinarians?-A Pilot Study. [PDF]

Vet Sci
Kovačević Z, Gračner GG, Tomanić D, Vlahović K, Šarić L, Novaković D, Galić I, Pajić K, Marić D, Samardžija M, Sič O.   +10 more
europepmc   +1 more source

Off-label use of Avastin in Pakistan: Lessons from the 2023 Punjab outbreak. [PDF]

J Public Health Res
Ali SM, Iqbal A, Hamid Z, Rauf SA, Haque MA.   +4 more
europepmc   +1 more source

Extemporaneous dermatological compounding in hospital pharmacies, Northwest Ethiopia. [PDF]

Front Public Health
Dagnew EM, Sendekie AK, Tsega W, Mekonnen BA, Getachew M.   +4 more
europepmc   +1 more source

Innovation in Onychomycosis Treatment Through Creative Compounding. [PDF]

Cureus
Hoffman K, Gorski M, Frey CP.
europepmc   +1 more source

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. [PDF]

J Am Acad Orthop Surg Glob Res Rev
Rahman OF, Lee SJ, Seeds WA.
europepmc   +1 more source